CA3097875A1 - Abcb5 ligands and substrates - Google Patents

Abcb5 ligands and substrates Download PDF

Info

Publication number
CA3097875A1
CA3097875A1 CA3097875A CA3097875A CA3097875A1 CA 3097875 A1 CA3097875 A1 CA 3097875A1 CA 3097875 A CA3097875 A CA 3097875A CA 3097875 A CA3097875 A CA 3097875A CA 3097875 A1 CA3097875 A1 CA 3097875A1
Authority
CA
Canada
Prior art keywords
abcb5
composition
pip2
pathway
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3097875A
Other languages
English (en)
French (fr)
Inventor
Markus H. Frank
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of CA3097875A1 publication Critical patent/CA3097875A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
CA3097875A 2018-04-25 2019-04-25 Abcb5 ligands and substrates Pending CA3097875A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662670P 2018-04-25 2018-04-25
US62/662,670 2018-04-25
PCT/US2019/029235 WO2019210109A1 (en) 2018-04-25 2019-04-25 Abcb5 ligands and substrates

Publications (1)

Publication Number Publication Date
CA3097875A1 true CA3097875A1 (en) 2019-10-31

Family

ID=68295729

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3097875A Pending CA3097875A1 (en) 2018-04-25 2019-04-25 Abcb5 ligands and substrates

Country Status (10)

Country Link
US (1) US12448461B2 (https=)
EP (1) EP3784249A4 (https=)
JP (2) JP7611701B2 (https=)
KR (2) KR102928177B1 (https=)
CN (1) CN112423765A (https=)
AU (2) AU2019257728A1 (https=)
CA (1) CA3097875A1 (https=)
MX (1) MX2020011297A (https=)
SG (1) SG11202010260XA (https=)
WO (1) WO2019210109A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111007240A (zh) * 2019-12-02 2020-04-14 中国医学科学院北京协和医院 一种基于crispr技术的均相酶免疫检验系统及其方法和应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2772535T1 (sl) 2006-05-31 2022-08-31 Children's Medical Center Corporation ABC5 pozitivne mezenhimske matične celice kot imunomodulatorji
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
AU2014262590B2 (en) 2013-05-10 2018-05-10 Children's Medical Center Corporation Wound healing and tissue engineering
CN115835882A (zh) * 2020-04-15 2023-03-21 儿童医学中心公司 靶向多形性胶质母细胞瘤中的abcb5
CN113082210B (zh) * 2021-03-09 2023-04-18 广州白云山医药集团股份有限公司白云山制药总厂 一种肿瘤化疗药物组合物
CN116445573A (zh) * 2022-08-30 2023-07-18 苏州大学 一种以抑制trim54泛素化降解stat2为靶点的抗病毒ade药物筛选方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3587465T2 (de) 1984-09-10 1994-01-20 Hsc Res Dev Corp Vielfache Drogen-Resistenz in Säugetierzellinien und Isolierung der determinanten Glykoprotein-DNS.
US5837258A (en) 1991-08-30 1998-11-17 University Of South Florida Induction of tissue, bone or cartilage formation using connective tissue growth factor
ES2329953T3 (es) 1996-04-19 2009-12-02 Osiris Therapeutics, Inc. Regeneracion e incremento de hueso utilizando celulas madre mesenquimales.
US6152142A (en) 1997-02-28 2000-11-28 Tseng; Scheffer C. G. Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries
AU749675B2 (en) 1998-03-13 2002-07-04 Mesoblast International Sarl Uses for human non-autologous mesenchymal stem cells
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
CA2266805C (en) 1998-03-27 2015-04-28 An-Go-Gen Inc. Cell-based gene therapy in the treatment of pulmonary disorders
AU2999199A (en) 1998-04-03 1999-10-25 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
PT1082410E (pt) 1998-05-29 2007-11-09 Osiris Therapeutics Inc Células estaminais mesenquimatosas humanas cd45+ e/ou fibroblastos+
JP2003510071A (ja) 1999-09-28 2003-03-18 ジェンテスト・コーポレーション Ｐ−糖タンパク質およびその使用
US6673606B1 (en) 2000-04-12 2004-01-06 The Children's Hospital Of Philadelphia Therapeutic uses for mesenchymal stromal cells
CA2411101C (en) 2000-06-05 2018-01-16 Brigham And Women's Hospital, Inc. A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof
US20040175366A1 (en) 2003-03-07 2004-09-09 Acell, Inc. Scaffold for cell growth and differentiation
EP1702061A4 (en) 2003-11-24 2007-05-02 Univ Rockefeller METHOD OF INSULATING A SELF-RENEWING, MULTIPOTENTIAL, SLOWLY CIRCULATING CELL
US20050186672A1 (en) 2004-01-27 2005-08-25 Reliance Life Sciences Pvt. Ltd. Tissue system with undifferentiated stem cells derived from corneal limbus
WO2006103685A2 (en) 2005-03-28 2006-10-05 Vision Research Foundation A method for cultivating cells derived from corneal limbal tissue and cells deived from corneal limbal tissue
KR101441843B1 (ko) 2005-10-18 2014-09-17 내셔날 쥬이쉬 헬스 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및 사용 방법
WO2007112097A2 (en) 2006-03-24 2007-10-04 Children's Medical Center Corporation Novel signature self renewal gene expression programs
GB0610778D0 (en) 2006-05-31 2006-07-12 Het Nl Kanker I Phosphatidylinositol phospahte and apoptosis
SI2772535T1 (sl) 2006-05-31 2022-08-31 Children's Medical Center Corporation ABC5 pozitivne mezenhimske matične celice kot imunomodulatorji
WO2008013492A1 (en) 2006-07-28 2008-01-31 Chundsell Medicals Ab Embryonic stem cell markers for cancer diagnosis and prognosis
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
EP2155248B1 (en) 2007-04-12 2015-06-10 The Brigham and Women's Hospital, Inc. Targeting abcb5 for cancer therapy
US9011840B2 (en) 2008-03-14 2015-04-21 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for wound healing and impaired tissue regeneration
EP3978928A1 (en) 2008-11-14 2022-04-06 The Brigham and Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
WO2010065711A1 (en) * 2008-12-04 2010-06-10 Adimab, Inc. An abcb5 epitope and antibodies thereto for the treatment of cancer
KR101138091B1 (ko) 2011-08-31 2012-04-24 세원셀론텍(주) 중간엽 줄기세포 기본 배양 배지 조성방법, 중간엽 줄기세포 기본 배양 배지 및 이를 이용하여 배양분화된 세포치료제
WO2014130518A1 (en) 2013-02-19 2014-08-28 Children's Medical Center Corporation Abcb5(+) stem cells for treating ocular disease
AU2014262590B2 (en) 2013-05-10 2018-05-10 Children's Medical Center Corporation Wound healing and tissue engineering
WO2016179576A1 (en) * 2015-05-07 2016-11-10 Bioxcel Corporation Novel immunomodulatory therapeutic strategies targeting tumors in cancer
WO2016184793A1 (en) * 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
ES2905558T3 (es) 2015-11-13 2022-04-11 Avellino Lab Usa Inc Procedimientos para el tratamiento de las distrofias corneales
WO2018185584A1 (en) 2017-04-05 2018-10-11 Pluristem Ltd. Methods and compositions for treating acute lung injury and respiratory distress syndrome
US20220184136A1 (en) 2019-03-28 2022-06-16 Children's Medical Center Corporation Highly functional manufactured abcb5+ mesenchymal stem cells
AU2020368845A1 (en) 2019-10-18 2022-05-12 Amniotics Ab Processes and apparatuses for obtaining amniotic mesenchymal stem cells from amniotic fluid and cells derived thereof
EP4125960A4 (en) 2020-03-30 2024-04-03 Children's Medical Center Corporation USING STEM CELLS TO TREAT EXCESSIVE INFLAMMATION
CN115835882A (zh) 2020-04-15 2023-03-21 儿童医学中心公司 靶向多形性胶质母细胞瘤中的abcb5
AU2021262864A1 (en) 2020-04-30 2022-11-17 Children's Medical Center Corporation Antibodies specific to ABCB5 and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111007240A (zh) * 2019-12-02 2020-04-14 中国医学科学院北京协和医院 一种基于crispr技术的均相酶免疫检验系统及其方法和应用

Also Published As

Publication number Publication date
JP2021522266A (ja) 2021-08-30
CN112423765A (zh) 2021-02-26
US20210188999A1 (en) 2021-06-24
US12448461B2 (en) 2025-10-21
MX2020011297A (es) 2020-11-18
AU2019257728A1 (en) 2020-11-12
SG11202010260XA (en) 2020-11-27
EP3784249A4 (en) 2022-03-02
KR102928177B1 (ko) 2026-02-20
KR20210005118A (ko) 2021-01-13
AU2025201810A1 (en) 2025-04-03
EP3784249A1 (en) 2021-03-03
JP2024154382A (ja) 2024-10-30
JP7611701B2 (ja) 2025-01-10
WO2019210109A1 (en) 2019-10-31
KR20260025888A (ko) 2026-02-24

Similar Documents

Publication Publication Date Title
US12448461B2 (en) ABCB5 ligands and substrates
KR101915942B1 (ko) 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
CN112566661B (zh) 喹啉衍生物与抗体的药物组合
CN113975393A (zh) 治疗吉非替尼耐药性癌症的方法
Garona et al. Preclinical efficacy of [V4Q5] dDAVP, a second generation vasopressin analog, on metastatic spread and tumor-associated angiogenesis in colorectal cancer
Spano et al. Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer
CN112292151B (zh) 抗pd-1抗体在制备治疗实体瘤的药物中的用途
CA3149112A1 (en) Novel therapeutic use
WO2019178438A1 (en) Abbv-621 in combination with anti-cancer agents for the treatment of cancer
US20230136997A1 (en) Targeting abcb5 in glioblastoma multiforme
KR102558988B1 (ko) 항암제 내성을 완화하고 항암제의 민감성을 강화하기 위한 약학적 조성물 및 그 용도
US20250262216A1 (en) Therapeutic uses of macrocyclic compounds
HK40047709A (en) Abcb5 ligands and substrates
TWI670079B (zh) 用於對抗具抗藥性癌症之組合物及方法
WO2015198332A1 (en) Compositions and methods for treating cancer
Kulasekararaj et al. The Non-transplant Treatment of Myelodysplastic Syndromes—What's on the Horizon?
HK40022838A (en) Macrocyclic compounds as ros1 kinase inhibitors
HK1259336A1 (zh) 用於治疗骨髓增生性病症的方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220928

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240909

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241219

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250207

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250207